Evofem Biosciences, Inc.

For the period ended Dec 31, 2024. Filed Mar 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 24, 2025

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Opening this filing…